Back to top
more

Marrone Bio Innovations, Inc. (MBII)

(Delayed Data from NSDQ)

$1.54 USD

1.54
84,904

+0.02 (1.32%)

Updated May 3, 2019 04:13 PM ET

After-Market: $1.53 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Marrone Bio's (MBII) Earnings and Revenues Miss Estimates in Q1

by Zacks Equity Research

Marrone Bio (MBII) witnessed increased sales of row crop products in the first quarter, offset by lower sales into specialty crop markets.

Marrone Bio Innovations, Inc. (MBII) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Marrone Bio Innovations, Inc. (MBII) delivered earnings and revenue surprises of -300% and 8.29%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Marrone Bio Innovations, Inc. (MBII) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Marrone Bio Innovations, Inc. (MBII) delivered earnings and revenue surprises of 0% and 3.85%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Koppers (KOP) Q4 Earnings Beat Estimates

by Zacks Equity Research

Koppers (KOP) delivered earnings and revenue surprises of 14.93% and 1.56%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Marrone (MBII) Expands the Existing Inventory Line of Credit

by Zacks Equity Research

Marrone's (MBII) increase in the line of credit for inventory provides it with greater flexibility to support its commercial expansion in the future.

Marrone Bio (MBII) Q3 Earnings In Line, Revenues Lag Estimates

by Zacks Equity Research

Marrone Bio's (MBII) third-quarter revenues were driven by strategic focus on global expansion in the major row crops.

Marrone Bio Innovations, Inc. (MBII) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Marrone Bio Innovations, Inc. (MBII) delivered earnings and revenue surprises of 0.00% and -8.61%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Will Marrone Bio Innovations, Inc. (MBII) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research

Marrone Bio Innovations, Inc. (MBII) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Marrone Bio (MBII) Herbicides Enter Late-Stage Development

by Zacks Equity Research

Marrone's (MBII) advancements strengthen its lead position as the supplier of choice for growers looking to meet the high demand for responsibly-grown food and fiber.

Marrone (MBII) & Terramera Partner to Boost Crop Protection

by Zacks Equity Research

Marrone (MBII) and Terramera are collaborating to bring technological and biological know-how to the market to enhance crop protection and create sustainable agricultural technologies.

Marrone Bio (MBII) Q2 Earnings and Revenues Miss Estimates

by Zacks Equity Research

Marrone Bio's (MBII) Q2 revenues were affected by severe drought in the western United States that led to reduced demand for insecticides and fungicides.

Marrone Bio Innovations, Inc. (MBII) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Marrone Bio Innovations, Inc. (MBII) delivered earnings and revenue surprises of -100.00% and -28.38%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Marrone Bio Innovations, Inc. (MBII) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

by Zacks Equity Research

Marrone Bio Innovations, Inc. (MBII) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Marrone Bio Innovations, Inc. (MBII) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Marrone Bio Innovations, Inc. (MBII) delivered earnings and revenue surprises of 0.00% and -0.20%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Will Marrone Bio Innovations, Inc. (MBII) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research

Marrone Bio Innovations, Inc. (MBII) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Anindya Barman headshot

Marrone Bio (MBII) Q3 Earnings In Line, Sales Trail Estimates

by Anindya Barman

Marrone Bio (MBII) posted lower year-over-year loss in Q3 on the back of a significant improvement in gross margins and lower operating expenses.

Will Marrone (MBII) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research

Marrone (MBII) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Anindya Barman headshot

Can Lithium Help Albemarle (ALB) Beat Earnings Again in Q2?

by Anindya Barman

While Albemarle (ALB) faces certain headwinds in its Bromine and Catalysts businesses, it should gain from strength in its Lithium unit.

    International Flavors (IFF) Q2 Earnings: What's in Store?

    by Zacks Equity Research

    International Flavors (IFF) anticipates gaining from acquired businesses as well as its multi-year productivity program. However, inflated material costs will restrain margins.

      What's in the Cards for WestRock (WRK) this Earnings Season?

      by Zacks Equity Research

      Despite cost headwinds, favorable demand, price and mix trends across its paper and packaging businesses will aid WestRock's (WRK) earnings performance in the third quarter.

        Marrone Bio (MBII) Q1 Earnings In Line, Revenues Rise Y/Y

        by Zacks Equity Research

        Marrone Bio (MBII) gained from manufacturing process improvement initiatives as well as favorable product mix in Q1.

          Is Marrone Bio Innovations (MBII) Stock a Solid Choice Right Now?

          by Zacks Equity Research

          Marrone Bio Innovations (MBII) is seeing solid earnings estimate revision activity and is a great company from a Zacks Industry Rank perspective.

            Marrone Bio Inks Regalia Maxx Distribution Deal With Disagro

            by Zacks Equity Research

            Marrone Bio's (MBII) latest move will provide growers in Central America with effective solutions for yield enhancement and disease control.

              Marrone Bio's Amplitude Available for 2018 Growing Season

              by Zacks Equity Research

              Marrone Bio's (MBII) unique biofungicide controls soil diseases and white molds on a broad range of large acre crops, pulses, tuber and root crops.

                Marrone Bio (MBII) Q3 Earnings, Revenues Miss Estimates

                by Zacks Equity Research

                Marrone Bio's (MBII) Q3 loss per share of 27 cents was wider than the Zacks Consensus Estimate of a loss of 24 cents.